Blocknomi
Key Takeaways Moderna received FDA clearance for mFlusiva, an mRNA-based seasonal influenza vaccine targeting adults 50 years and above. Shares of MRNA gained 3.6% to reach $58.30 in premarket trading…
Related articles
-
Novo Nordisk (NVO) Stock Tumbles 9% as ZEUS Trial Falls Short of Cardiovascular Goals
Blocknomi Published 31.07.2026 14:04
-
China Adds 20 Tonnes to Gold Reserves as Hong Kong Expands Bullion Hub
Blocknomi Published 09.08.2026 01:01
-
Quantes Announces Revenue-Sharing Model Backed by Commercial AI Compute Infrastructure
Crypto Daily Published 05.08.2026 13:17
-
SHIB’s 37% Rally Evaporates as On-Chain Data Shows Whales Dumped Into Retail FOMO
BlockchainReporter Published 28.07.2026 05:00
-
Advanced Micro Devices (AMD) Stock Drops Despite Crushing Q2 Earnings Expectations
Blocknomi Published 06.08.2026 16:57
-
Bitcoin Bear Market Over? Top Analysts Turn Bullish, but History Says Otherwise
CryptoPotato Published 08.08.2026 07:38
-
Cardano Founder Blasts Ark Invest Director's Bias Over Criticism
U.Today Published 25.07.2026 14:30
-
Backblaze (BLZE) Stock: Company to Showcase AI Storage Solutions at Ai4 2026
Blocknomi Published 03.08.2026 19:14